Home
/
Barinthus Biotherapeutics plc.
/
Financials
/
Quarterly
Barinthus Biotherapeutics plc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Barinthus Biotherapeutics plc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$0
Nov 7, 2025
Q3
2025
Sep 30, 2024
$14.97M
Nov 7, 2025
Q2
2024
Jun 30, 2024
$0
Aug 8, 2024
Q1
2024
Mar 31, 2024
$0
May 13, 2024
Q3
2024
Sep 30, 2023
$0
Nov 6, 2024
Q2
2024
Jun 30, 2023
$334.0K
Aug 8, 2024
Q1
2024
Mar 31, 2023
$468.0K
May 13, 2024
Q3
2023
Sep 30, 2022
$6.17M
Nov 9, 2023
Q2
2023
Jun 30, 2022
$17.06M
Aug 10, 2023
Q1
2023
Mar 31, 2022
$15.02M
May 12, 2023
Q3
2022
Sep 30, 2021
$19.0K
Nov 10, 2022
Q2
2022
Jun 30, 2021
$35.0K
Aug 9, 2022
Q1
2022
Mar 31, 2021
$215.0K
May 11, 2022
Q3
2021
Sep 30, 2020
$3.25M
Nov 12, 2021
Q2
2021
Jun 30, 2020
$511.0K
Aug 12, 2021
Q1
2021
Mar 31, 2020
$705.0K
Jun 14, 2021
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($14.57M)
Nov 7, 2025
Q2
2025
Jun 30, 2025
($21.12M)
Aug 7, 2025
Q1
2025
Mar 31, 2025
($19.65M)
May 7, 2025
Q3
2025
Sep 30, 2024
($8.11M)
Nov 7, 2025
Q2
2025
Jun 30, 2024
($16.93M)
Aug 7, 2025
Q1
2025
Mar 31, 2024
($15.49M)
May 7, 2025
Q3
2024
Sep 30, 2023
($14.07M)
Nov 6, 2024
Q2
2024
Jun 30, 2023
($23.80M)
Aug 8, 2024
Q1
2024
Mar 31, 2023
($18.18M)
May 13, 2024
Q3
2023
Sep 30, 2022
$8.24M
Nov 9, 2023
Q2
2023
Jun 30, 2022
$15.69M
Aug 10, 2023
Q1
2023
Mar 31, 2022
$2.60M
May 12, 2023
Q3
2022
Sep 30, 2021
($4.56M)
Nov 10, 2022
Q2
2022
Jun 30, 2021
($15.93M)
Aug 9, 2022
Q1
2022
Mar 31, 2021
($15.27M)
May 11, 2022
Q3
2021
Sep 30, 2020
$158.0K
Nov 12, 2021
Q2
2021
Jun 30, 2020
($3.59M)
Aug 12, 2021
Q1
2021
Mar 31, 2020
($3.82M)
Jun 14, 2021
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($15.07M)
Nov 7, 2025
Q2
2025
Jun 30, 2025
($23.32M)
Aug 7, 2025
Q1
2025
Mar 31, 2025
($20.60M)
May 7, 2025
Q3
2025
Sep 30, 2024
($9.38M)
Nov 7, 2025
Q2
2025
Jun 30, 2024
($18.29M)
Aug 7, 2025
Q1
2025
Mar 31, 2024
($16.91M)
May 7, 2025
Q3
2024
Sep 30, 2023
($16.11M)
Nov 6, 2024
Q2
2024
Jun 30, 2023
($26.34M)
Aug 8, 2024
Q1
2024
Mar 31, 2023
($21.48M)
May 13, 2024
Q3
2023
Sep 30, 2022
$7.24M
Nov 9, 2023
Q2
2023
Jun 30, 2022
$13.24M
Aug 10, 2023
Q1
2023
Mar 31, 2022
$654.0K
May 12, 2023
Q3
2022
Sep 30, 2021
($5.54M)
Nov 10, 2022
Q2
2022
Jun 30, 2021
($16.85M)
Aug 9, 2022
Q1
2022
Mar 31, 2021
($6.17M)
May 11, 2022
Q3
2021
Sep 30, 2020
($1.43M)
Nov 12, 2021
Q2
2021
Jun 30, 2020
($4.34M)
Aug 12, 2021
Q1
2021
Mar 31, 2020
($4.65M)
Jun 14, 2021